NCT03581773 2025-03-05
DARENCA4
University of Aarhus
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT02606994 2019-02-06
TPvsM
Oral Defense, LLC
Phase 2 Terminated
NCT02324335 2019-01-16
Brilacidin
Innovation Pharmaceuticals, Inc.
Phase 2 Completed
NCT02885376 2018-12-21
Study of Dentoxol® Mouthrinse for Oral Mucositis
Ingalfarma SpA
Phase 2 Completed
NCT01898091 2017-03-06
OM
Medical University of South Carolina
Phase 2 Completed
NCT00698204 2014-06-05
Cox-2 Inhibition in Radiation-induced Oral Mucositis
UConn Health
Phase 2 Completed
NCT01247246 2014-05-26
Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer
SciClone Pharmaceuticals
Phase 2 Unknown
NCT00965172 2012-03-22
Caphosol in Sarcoma Patients With Mucositis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01083875 2010-03-18
Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region
Access Pharmaceuticals, Inc.
Phase 2 Completed
NCT00230191 2007-01-15
Safety and Efficacy of RK0202 in Oral Mucositis
RxKinetix
Phase 2 Completed